Compare British American Tobacco PLC (BTI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Vertex Pharmaceuticals Incorporated — how do they compare? British American Tobacco PLC trades at $56.8 (market cap $122.36B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: British American Tobacco PLC and Vertex Pharmaceuticals Incorporated are close in size by market cap, and British American Tobacco PLC pays a 5.88% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| BTI | VRTX | |
|---|---|---|
Market Cap | $122.36B | $134.25B |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $529.65 |
52-Week Low | $50.39 | $376.62 |
Enterprise Value | $166.31B | $128.37B |
Dividend Yield | 5.88% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
